Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.

Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC Jr, Mills GB, Fang X.

Cancer Res. 2006 Mar 1;66(5):2740-8.

2.

LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.

Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, Yamada T, Kimura T, Kuwabara A, Ohta H, Im DS, Kurose H, Takeyoshi I, Sato K, Okajima F.

Carcinogenesis. 2009 Mar;30(3):457-65. doi: 10.1093/carcin/bgp011. Epub 2009 Jan 7.

PMID:
19129242
3.

Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.

Jeong KJ, Park SY, Seo JH, Lee KB, Choi WS, Han JW, Kang JK, Park CG, Kim YK, Lee HY.

Exp Mol Med. 2008 Dec 31;40(6):607-16.

4.

Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.

Park SJ, Lee KP, Kang S, Chung HY, Bae YS, Okajima F, Im DS.

Cell Signal. 2013 Nov;25(11):2147-54. doi: 10.1016/j.cellsig.2013.07.001. Epub 2013 Jul 6.

PMID:
23838008
5.

Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites.

Sako A, Kitayama J, Shida D, Suzuki R, Sakai T, Ohta H, Nagawa H.

J Surg Res. 2006 Jan;130(1):94-101. Epub 2005 Sep 19.

PMID:
16171822
6.

Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells.

Hurst JH, Henkel PA, Brown AL, Hooks SB.

Cell Signal. 2008 Feb;20(2):381-9. Epub 2007 Nov 7.

PMID:
18083345
7.
8.

Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.

Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, Jaffe RB.

J Natl Cancer Inst. 2001 May 16;93(10):762-8.

PMID:
11353786
9.

Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake.

Yea K, Kim J, Lim S, Park HS, Park KS, Suh PG, Ryu SH.

J Mol Med (Berl). 2008 Feb;86(2):211-20. Epub 2007 Oct 9.

PMID:
17924084
10.
11.

Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.

Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB.

J Biol Chem. 2004 Mar 5;279(10):9653-61. Epub 2003 Dec 11.

12.

Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells.

Oyesanya RA, Lee ZP, Wu J, Chen J, Song Y, Mukherjee A, Dent P, Kordula T, Zhou H, Fang X.

FASEB J. 2008 Aug;22(8):2639-51. doi: 10.1096/fj.07-101428. Epub 2008 Mar 24.

13.

Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells.

Jeon ES, Heo SC, Lee IH, Choi YJ, Park JH, Choi KU, Park DY, Suh DS, Yoon MS, Kim JH.

Exp Mol Med. 2010 Apr 30;42(4):280-93.

14.

Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells.

Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh DS, Yoon MS, Chang CL, Jung JS, Kim JH.

Stem Cells. 2008 Mar;26(3):789-97. Epub 2007 Dec 6.

15.

Epidermal growth factor increases lysophosphatidic acid production in human ovarian cancer cells: roles for phospholipase D2 and receptor transactivation.

Snider AJ, Zhang Z, Xie Y, Meier KE.

Am J Physiol Cell Physiol. 2010 Jan;298(1):C163-70. doi: 10.1152/ajpcell.00001.2009. Epub 2009 Oct 28.

16.
17.

Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.

Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E.

Cancer Res. 2004 Aug 15;64(16):5720-7.

18.

Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.

Mukherjee A, Wu J, Barbour S, Fang X.

J Biol Chem. 2012 Jul 20;287(30):24990-5000. doi: 10.1074/jbc.M112.340083. Epub 2012 Jun 3.

19.

Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor.

Chou CH, Wei LH, Kuo ML, Huang YJ, Lai KP, Chen CA, Hsieh CY.

Carcinogenesis. 2005 Jan;26(1):45-52. Epub 2004 Oct 7.

PMID:
15471896
20.

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.

Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB.

J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42. doi: 10.1093/jnci/djn378. Epub 2008 Nov 11.

Supplemental Content

Support Center